Medication errors are one of the major causes of preventable adverse drug effects. Errors associated with prescribing and dispensing are prevalent. Electronic prescribing (e-prescribing) offers a solution to mitigate these errors by enhancing legibility, dosing, and remote accessibility. This study aimed to investigate the perceptions of prescribers and pharmacists regarding the adoption and implementation of electronic prescribing (e-prescribing) and electronic medication management (EMM) systems in public health facilities of Dessie City administration, Northeast Ethiopia. A cross-sectional survey was conducted from April 20 to June 25, 2022, in public health facilities of Dessie City administration. A structured self-administered questionnaire was employed to collect data from 201 prescribers and pharmacists. The study was based on the unified theory of acceptance and use of technology model. Data were analyzed using SPSS version 25 and SmartPLS version 4.0. Nearly 34 (72.5%) of the respondents were males. The majority (88.6%) of the participants had a positive perception towards the use of e-prescribing and EMM systems. The mean score for performance expectancy, effort expectancy, and facilitating conditions were 4.29, 4.26, and 4.18, respectively. Perceived facilitating conditions (β = 0.271, p = 0.003), price value (β = 0.239, p = 0.002), performance expectancy (β = 0.237, p = 0.008), and effort expectancy (β = 0.176, p = 0.008) were found to affect the acceptance of e-prescribing and EMM systems among prescribers and pharmacists. Prescribers and pharmacists have a positive perception towards the use of e-prescribing and EMM systems. Perceived facilitating conditions, price value, performance expectancy, and effort expectancy significantly influence acceptance. The effect of perceived credibility on acceptance was fully mediated by performance expectancy.

The authors have declared no competing interest.

N/A

The author(s) received no specific funding for this work.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

College of Medicine and Health Science Research Ethics Review Committee (RERC), Wollo University (Ref. № - RCSPG-130-14)

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.